Galapagos announces changes to Executive Committee
22 Dicembre 2022 - 10:01PM
Mechelen, Belgium; 22
December 2022, 22.01
CET; Galapagos NV (Euronext & NASDAQ:
GLPG) today announced
changes in the
Executive
Committee effective
1 January
2023.
Dr. Walid Abi-Saab has decided to retire from the
company as Chief Medical Officer and member of the Executive
Committee, effective 31 December 2022. He will stay with Galapagos
until 31 May 2023 to ensure a smooth transition.
The company also announces the retirement of André
Hoekema who joined Galapagos in 2005 as Chief Business Officer and
member of the Executive Committee.
Dr. Paul Stoffels1, CEO and Chairman of Galapagos
said: “On behalf of the Board, I want to thank Walid and André for
their commitment and contributions throughout the years. Walid
joined the company in early 2017 and led it through a critical and
transformative phase, including the successful completion of the
Phase 3 studies of filgotinib in rheumatoid arthritis and
ulcerative colitis. We recognize his important contribution to
building out the development organization and to bringing our
company to the fully integrated biotech that we are today. Since
joining Galapagos as a pre-IPO company in 2005, André has led the
business development function and played an important role in the
company’s growth through a large series of pharma partnerships,
including the Gilead collaboration.”
The company anticipates announcing a Head of
R&D and Executive Committee member in the first half of 2023.
Until such appointment, Dr. Paul Stoffels1 will act as Head of
R&D ad interim. Additionally, the company’s senior leadership
team has been strengthened with key hires and internal promotions
in Research, Development, Business Development and Commercial.
Furthermore, the Board of Directors of Galapagos
appointed two new members to the Executive Committee:
- Ms. Annelies Missotten, Chief Human
Resources Officer
- Annelies joined Galapagos early
2018 from GSK, where she was HR Business Leader of Global
Vaccines Commercial & Global Vaccines Strategic
Partnerships
- Ms. Valeria Cnossen, General
Counsel, also responsible for Compliance & Ethics, the
Corporate Secretary Office and Intellectual Property
- Valeria joined Galapagos in August
2022. She previously was General Counsel of the Consumer Health
Group of Johnson & Johnson and held leadership roles in the
Pharmaceuticals Group and Medical Devices Group of Johnson &
Johnson
“I am very pleased that our Executive Committee is
strengthened with key strategic positions to help drive future
growth. Annelies and Valeria bring a wealth of expertise and will
be instrumental in setting and executing on our human capital
strategy and our corporate governance,” commented Dr. Paul
Stoffels, CEO and Chairman of Galapagos.
About
GalapagosGalapagos is a fully integrated biotechnology
company focused on discovering, developing, and commercializing
innovative medicines. We are committed to improving patients’ lives
worldwide by targeting diseases with high unmet needs. Our R&D
capabilities cover multiple drug modalities, including small
molecules and cell therapies. Our portfolio comprises discovery
through to Phase 4 programs in immunology, oncology, and other
indications. Our first medicine for rheumatoid arthritis and
ulcerative colitis is available in Europe and Japan. For additional
information, please visit www.glpg.com or follow us
on LinkedIn or Twitter.
Except for filgotinib’s approval for the treatment
of moderately to severely rheumatoid arthritis and ulcerative
colitis by the relevant regulatory authorities in the European
Union, Great Britain, and Japan, our drug candidates are
investigational; their efficacy and safety have not been fully
evaluated by any regulatory authority.
ContactInvestors:Sofie
Van GijselHead of Investor Relations+1 781 296 1143
Sandra CauwenberghsDirector Investor Relations+32
495 58 46 63ir@glpg.com
Media:Marieke VermeerschHead of
Corporate Communication+32 479 490 603media@glpg.com
Forward-looking statementsThis
press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including statements regarding the announced leadership
transition and Executive Committee appointments, benefits the
company expects to realize from new additions to its Executive
Committee, its ability to accelerate its development activities and
its strategic direction model, and other statements
contained in this press release that are not historical facts
and statements identified by words such as “expects,”
“anticipates,” “intends,” “vision,” “aims”, and “plans,” or words
of similar meaning. These forward-looking statements are subject to
risks, uncertainties and other factors that could cause actual
results to differ materially from those referred to in the
forward-looking statements and, therefore, the reader should not
place undue reliance on them. These risks, uncertainties and other
factors include, without limitation, the risk that we may not be
able to realize the expected benefits from our planned leadership
transition, that our leadership transition may be disruptive to our
business operations, and those risks and uncertainties identified
in our Annual Report on Form 20-F for the year ended 31 December
2021 and our subsequent filings with the SEC. The forward-looking
statements contained herein are based on management’s current
expectations and beliefs and speak only as of the date hereof, and
Galapagos makes no commitment to update or publicly release any
revisions to forward-looking statements in order
to reflect new information or subsequent events,
circumstances or changes in expectations.
1 Acting via Stoffels IMC BV
- Galapagos announces changes to Executive Committee
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Mag 2023 a Mag 2024